Overview: Nicotine Screen TestIntroduction: The Nicotine Screen Test detects nicotine to diagnose tobacco exposure, causing respiratory or heart issues. Following 2023 CDC guidelines, it uses biochemistry methods for high specificity, supporting toxicology screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in toxicology for patients with suspected tobacco exposure, often in occupational or health screening settings.
Other Names: Nicotine Assay, Tobacco Exposure Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: Nicotine screening began in the 1980s with tobacco research. Biochemical methods improved in the 2000s, enhancing detection sensitivity.
Purpose: Detects nicotine to diagnose tobacco exposure, guides treatment, and evaluates patients with respiratory or heart issues.
Test Parameters: 1. Nicotine Presence
Pretest Condition: No fasting required. Collect urine, serum, plasma, or saliva. Report history of respiratory issues, heart issues, or tobacco exposure.
Specimen: Urine (sterile container, 5-20 mL), Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document respiratory issues, heart issues, smoking history, or exposure to secondhand smoke. Include current medications, especially nicotine replacement therapy.
Consent: Written consent required, detailing the tests purpose, tobacco exposure implications, and risks of sample collection.
Procedural Considerations: Uses biochemistry methods to detect nicotine in specimens. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for tobacco exposure screening.
Factors Affecting Result Accuracy: Contamination, improper sample storage, or low nicotine levels can affect results. Sample quality impacts sensitivity.
Clinical Significance: Positive nicotine detection confirms tobacco exposure, guiding smoking cessation or environmental intervention. Negative results may require cotinine testing.
Specialist Consultation: Consult a pulmonologist or cardiologist for result interpretation and treatment planning.
Additional Supporting Tests: Cotinine testing, spirometry, or carbon monoxide testing to confirm tobacco exposure diagnosis.
Test Limitations: Detection window is short; clinical correlation is needed. Secondhand smoke may cause false positives.
References: CDC Tobacco Guidelines, 2023; Nicotine & Tobacco Research, Benowitz NL, 2022.
